Smith-Lemli-Opitz Syndrome Clinical Trial
Official title:
Smith-Lemli-Opitz Syndrome: A Longitudinal Clinical Study of Patients Receiving Cholesterol Supplementation
The purpose of this study is to learn about Smith-Lemli-Opitz Syndrome (SLOS). SLOS is an
inherited condition that is caused by the body not making an enzyme as it should. The body
needs the enzyme to help make cholesterol. SLOS can cause many health problems including slow
growth and development, eating disorders, sleep disorders, behavior disorders, and eye
diseases. Severe SLOS leads to birth defects and mental retardation and in many cases early
death. The investigators plan to measure cholesterol and other sterol levels, perform
clinical observations, whole body testing and imaging (brain MRIs), to learn more about the
disease and its progression, differences in the clinical features among individuals with
SLOS, and look at the effect of cholesterol supplementation in this condition.
The study is an interventional study to characterize disease progression and correlations
between clinical, biochemical and physiological features of the disease. The main hypothesis
is that dietary cholesterol supplementation does not improve features of SLOS related to the
brain (e.g. IQ, behavior).
Smith-Lemli-Opitz syndrome (SLOS) is a disorder of cholesterol synthesis, or production. It is caused by mutations in the DHCR7 gene which encodes for 7-dehydrocholesterol- Δ7-reductase, an enzyme necessary for the production of cholesterol in the body. Affected individuals exhibit multiple malformations and mental retardation. The features of SLOS are thought to be primarily related to cholesterol deficiency and accumulation of cholesterol precursors. However, the clinical phenotype is not well characterized, the biochemical pathogenesis is incompletely understood, and there is no proven therapy for this devastating condition. Thus our primary objective is to better define the clinical and biochemical phenotypes of the disease using a natural history study design. The study will contribute to creating a comprehensive SLOS patient registry, identify biomarkers that can be used for diagnostic testing, screening and outcome measures in future therapeutic trials. All patients with SLOS receive dietary cholesterol supplementation with the hope that cholesterol supplementation will improve the clinical manifestation of the disease. However, there is no evidence supporting a clinical benefit of cholesterol supplementation. Thus a secondary objective of the study is to determine if cholesterol intake correlates with changes in whole body cholesterol homeostasis and clinical end-points. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01434745 -
SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation
|
N/A | |
Completed |
NCT00001721 -
Study of Smith-Lemli-Opitz Syndrome
|
||
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Recruiting |
NCT00004347 -
Phase II Study of Dietary Cholesterol for Smith-Lemli-Opitz Syndrome
|
Phase 2 | |
Completed |
NCT03720990 -
Smith-Lemli-Opitz Syndrome and Cholic Acid
|
Phase 1/Phase 2 | |
Completed |
NCT00114634 -
Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome
|
Phase 2 | |
Completed |
NCT00017732 -
Estimation of the Carrier Frequency and Incidence of Smith-Lemli-Opitz Syndrome in African Americans
|
N/A | |
Completed |
NCT00064792 -
Simvastatin Therapy in Smith-Lemli-Opitz Syndrome
|
Phase 2 | |
Recruiting |
NCT05642221 -
Functional Near-Infrared Spectroscopy (fNIRS) Combined With Diffuse Correlation Spectroscopy (DCS) in Neurocognitive Disease as Compared to Healthy Neurotypical Controls
|
||
Completed |
NCT00272844 -
Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome
|
Phase 1/Phase 2 | |
Recruiting |
NCT01773278 -
Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
|
Phase 2 | |
Completed |
NCT00070850 -
Prenatal Screening For Smith-Lemli-Opitz Syndrome
|
Phase 2 |